These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28893921)

  • 1. Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD.
    Arnold R; Pianta TJ; Pussell BA; Kirby A; O'Brien K; Sullivan K; Holyday M; Cormack C; Kiernan MC; Krishnan AV
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1569-1577. PubMed ID: 28893921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.
    Lepage L; Dufour AC; Doiron J; Handfield K; Desforges K; Bell R; Vallée M; Savoie M; Perreault S; Laurin LP; Pichette V; Lafrance JP
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2136-42. PubMed ID: 26576619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients.
    Yu MY; Yeo JH; Park JS; Lee CH; Kim GH
    PLoS One; 2017; 12(3):e0173542. PubMed ID: 28328954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the tolerability and efficacy of sodium polystyrene sulfonate for long-term management of hyperkalemia in patients with chronic kidney disease.
    Georgianos PI; Liampas I; Kyriakou A; Vaios V; Raptis V; Savvidis N; Sioulis A; Liakopoulos V; Balaskas EV; Zebekakis PE
    Int Urol Nephrol; 2017 Dec; 49(12):2217-2221. PubMed ID: 29027620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.
    Sarafidis PA; Blacklock R; Wood E; Rumjon A; Simmonds S; Fletcher-Rogers J; Ariyanayagam R; Al-Yassin A; Sharpe C; Vinen K
    Clin J Am Soc Nephrol; 2012 Aug; 7(8):1234-41. PubMed ID: 22595825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Sodium Polystyrene Sulfonate Dosing Strategies in the Inpatient Management of Hyperkalemia.
    Mistry M; Shea A; Giguère P; Nguyen ML
    Ann Pharmacother; 2016 Jun; 50(6):455-62. PubMed ID: 27048188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease?
    Ramos CI; González-Ortiz A; Espinosa-Cuevas A; Avesani CM; Carrero JJ; Cuppari L
    Nephrol Dial Transplant; 2021 Nov; 36(11):2049-2057. PubMed ID: 33247727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
    Agarwal R; Rossignol P; Garza D; Mayo MR; Warren S; Arthur S; Romero A; White WB; Williams B
    Am J Nephrol; 2018; 48(3):172-180. PubMed ID: 30176673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of hyperkalemia with clinical outcomes in advanced chronic kidney disease.
    Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F
    Nefrologia (Engl Ed); 2019; 39(5):513-522. PubMed ID: 31027897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
    JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dietary management of potassium in children with CKD stages 2-5 and on dialysis-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce.
    Desloovere A; Renken-Terhaerdt J; Tuokkola J; Shaw V; Greenbaum LA; Haffner D; Anderson C; Nelms CL; Oosterveld MJS; Paglialonga F; Polderman N; Qizalbash L; Warady BA; Shroff R; Vande Walle J
    Pediatr Nephrol; 2021 Jun; 36(6):1331-1346. PubMed ID: 33730284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic renal disease progression: treatment strategies and potassium intake.
    Sinha AD; Agarwal R
    Semin Nephrol; 2013 May; 33(3):290-9. PubMed ID: 23953806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium-Polystyrene Sulfonate Decreases Inter-Dialytic Hyperkalemia in Patients Undergoing Maintenance Hemodialysis: A Prospective, Randomized, Crossover Study.
    Wang J; Lv MM; Zach O; Wang LY; Zhou MY; Song GR; Zhang X; Lin HL
    Ther Apher Dial; 2018 Dec; 22(6):609-616. PubMed ID: 30109784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of case reports on hyperkalemia induced by dietary intake: not restricted to chronic kidney disease patients.
    Te Dorsthorst RPM; Hendrikse J; Vervoorn MT; van Weperen VYH; van der Heyden MAG
    Eur J Clin Nutr; 2019 Jan; 73(1):38-45. PubMed ID: 29588531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Novel Potassium Binders Liberate People with Chronic Kidney Disease from the Low-Potassium Diet? A Cautionary Tale.
    St-Jules DE; Clegg DJ; Palmer BF; Carrero JJ
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):467-472. PubMed ID: 34670798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis.
    Mah JY; Choy SW; Roberts MA; Desai AM; Corken M; Gwini SM; McMahon LP
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012616. PubMed ID: 32390133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Sodium Bicarbonate in CKD Stages 3 and 4: A Randomized, Placebo-Controlled, Multicenter Clinical Trial.
    Melamed ML; Horwitz EJ; Dobre MA; Abramowitz MK; Zhang L; Lo Y; Mitch WE; Hostetter TH
    Am J Kidney Dis; 2020 Feb; 75(2):225-234. PubMed ID: 31699517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study.
    Pergola PE; Spiegel DM; Warren S; Yuan J; Weir MR
    Am J Nephrol; 2017; 46(4):323-332. PubMed ID: 29017162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.